Ventyx Biosciences, Inc. (NASDAQ:VTYX) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) have been assigned a consensus recommendation of “Moderate Buy” from the five ratings firms that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $10.00.

A number of equities research analysts have recently issued reports on the company. HC Wainwright reiterated a “neutral” rating and issued a $6.00 target price on shares of Ventyx Biosciences in a research note on Monday, November 11th. Oppenheimer reaffirmed an “outperform” rating and issued a $9.00 price objective (down previously from $10.00) on shares of Ventyx Biosciences in a research report on Friday, November 8th.

Ventyx Biosciences Trading Down 1.8 %

Shares of NASDAQ VTYX opened at $2.24 on Tuesday. The stock has a fifty day moving average price of $2.30 and a 200 day moving average price of $2.36. Ventyx Biosciences has a 12-month low of $1.67 and a 12-month high of $11.48. The company has a market cap of $158.39 million, a P/E ratio of -0.95 and a beta of 0.48.

Insider Transactions at Ventyx Biosciences

In related news, CEO Raju Mohan purchased 238,248 shares of the company’s stock in a transaction that occurred on Friday, November 22nd. The stock was acquired at an average price of $1.83 per share, for a total transaction of $435,993.84. Following the completion of the purchase, the chief executive officer now owns 1,913,276 shares in the company, valued at approximately $3,501,295.08. This represents a 14.22 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider John Nuss sold 13,161 shares of the stock in a transaction on Thursday, December 19th. The shares were sold at an average price of $2.26, for a total transaction of $29,743.86. Following the transaction, the insider now owns 485,701 shares in the company, valued at $1,097,684.26. This trade represents a 2.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 18.18% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Deerfield Management Company L.P. Series C raised its stake in Ventyx Biosciences by 64.6% during the second quarter. Deerfield Management Company L.P. Series C now owns 5,829,570 shares of the company’s stock worth $13,466,000 after acquiring an additional 2,287,570 shares during the period. Sio Capital Management LLC grew its holdings in shares of Ventyx Biosciences by 153.2% during the third quarter. Sio Capital Management LLC now owns 1,971,948 shares of the company’s stock valued at $4,299,000 after purchasing an additional 1,193,024 shares during the last quarter. Vestal Point Capital LP raised its position in shares of Ventyx Biosciences by 31.2% during the 3rd quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company’s stock worth $3,760,000 after purchasing an additional 410,000 shares during the period. Acadian Asset Management LLC bought a new stake in shares of Ventyx Biosciences in the 2nd quarter worth approximately $608,000. Finally, XTX Topco Ltd acquired a new position in Ventyx Biosciences during the 3rd quarter valued at approximately $246,000. 97.88% of the stock is currently owned by institutional investors.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.